&lt;p&gt;Combined Therapeutic Effects of &lt;sup&gt;131&lt;/sup&gt;I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer&lt;/p&gt;

Wu, Pingping; Zhu, Huayun; Zhuang, Yan; Sun, Xiaofeng; Gu, Ning

doi:10.2147/ijn.s215137

Cited by 14 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the past, sdAbs against a variety of membrane-bound cancer biomarkers such as CEA (49), EGFR (52), HER2 (49), PSMA (53), and CD20 (54,55) have been successfully evaluated as in vivo theranostic tracers, using a variety of radionuclides in (non-)clinical studies. The most advanced sdAb under clinical evaluation is a sdAb targeting HER2 that after labelling with 68 Ga, identified both primary HER2 + tumors and related metastasis as early as one hour post injection in a phase I study (56). Recently, the biodistribution of the same sdAb labelled with 131 I in six healthy volunteers and three patients with metastatic breast cancer was reported (57).…”

Section: Single Domain Antibodiesmentioning

confidence: 99%

“…Krasniqi et al generated sdAbs targeting CD20 and used them as radiolabeled agents for imaging and TRNT of CD20 + lymphomas (54). In a preclinical model of CD20 + lymphoma, micro-PET/CT images generated in mice that received a 68 Galabelled CD20-targeting sdAb revealed specific tumor targeting as early as one hour post injection. The background signal was low in all non-target organs, except the kidneys and bladder through which the unbound fraction is cleared rapidly.…”

Section: Non-hodgkin Lymphomamentioning

confidence: 99%

See 1 more Smart Citation

Radiotheranostic Agents in Hematological Malignancies

et al. 2022

View full text Add to dashboard Cite

Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, researchers have developed theranostic agents based on Ab fragments or small Ab mimetics such as peptides, affibodies or single-chain Abs with improved tumor-targeting capacities. Theranostics combine diagnostic and therapeutic capabilities into a single pharmaceutical agent; this dual application can be easily achieved after conjugation to radionuclides. The past decade has seen a trend to increased specificity, fastened pharmacokinetics, and personalized medicine. In this review, we discuss the different strategies introduced for the noninvasive detection and treatment of hematological malignancies by radiopharmaceuticals. We also discuss the future applications of these radiotheranostic agents.

show abstract

Section: Single Domain Antibodiesmentioning

confidence: 99%

Section: Non-hodgkin Lymphomamentioning

confidence: 99%

Radiotheranostic Agents in Hematological Malignancies

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, the radio-chemotherapy combination Cet–PEG–PLA–5FU- 131 I (5 FU 0.625 µg/mL and 1.85 MBq/mL of 131 I) resulted in significantly higher cytotoxicity when compared to monotherapy. Consequently, the Cet–PEG–PLA–5FU- 131 I nanoparticle system showed prolonged blood circulation and effective tumor accumulation [ 62 ].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer

et al. 2022

View full text Add to dashboard Cite

Nanoparticles are excellent platforms for several biomedical applications, including cancer treatment. They can incorporate different molecules to produce combinations of chemotherapeutic agents, radionuclides, and targeting molecules to improve the therapeutic strategies against cancer. These specific nanosystems are designed to have minimal side effects on healthy cells and better treatment efficacy against cancer cells when compared to chemotherapeutics, external irradiation, or targeted radiotherapy alone. In colorectal cancer, some metal and polymeric nanoparticle platforms have been used to potentialize external radiation therapy and targeted drug delivery. Polymeric nanoparticles, liposomes, albumin-based nanoparticles, etc., conjugated with PEG and/or HLA, can be excellent platforms to increase blood circulation time and decrease side effects, in addition to the combination of chemo/radiotherapy, which increases therapeutic efficacy. Additionally, radiolabeled nanoparticles have been conjugated to target specific tissues and are mainly used as agents for diagnosis, drug/gene delivery systems, or plasmonic photothermal therapy enhancers. This review aims to analyze how nanosystems are shaping combinatorial therapy and evaluate their status in the treatment of colorectal cancer.

show abstract

“…In this regard, the efficacy of these chemotherapeutic drugs is not ideal due to significant toxicity and side effects, as well as the putative induction of multi-drug resistance. Although complementary modalities such electroporation and nanoparticles have dramatically improved the therapeutic efficacy of chemotherapeutic agents in CRC, the main limitation of chemotherapy technique is severe cytotoxicity [85][86][87][88][89]. Actually, about 50% of patients with metastatic CRC show a progressive disease within 7-9 months after drug treatment, with a median survival of 20 months and a 5-year survival rate of less than 5%.…”

Section: Anti-cancer Effects Colorectal Cancermentioning

confidence: 99%

Pien Tze Huang (PZH) as a Multifunction Medicinal Agent in Traditional Chinese Medicine (TCM): a review on cellular, molecular and physiological mechanisms

Chen¹

2021

Cancer Cell Int

View full text Add to dashboard Cite

Relevance Pien Tze Huang (PZH) is a well-known Traditional Chinese Medicine (TCM), characterized by a multitude of pharmacological effects, such as hepatoprotection and inhibition of inflammation and cell proliferative conditions. Many of these effects have been validated at the cellular, molecular and physiological levels but, to date, most of these findings have not been comprehensively disclosed. Objectives This review aims to provide a critical summary of recent studies focusing on PZH and its multiple pharmacological effects. As a result, we further discuss some novel perspectives related to PZH’s mechanisms of action and a holistic view of its therapeutic activities. Methods A systematic review was performed focusing on PZH studies originated from original scientific resources. The scientific literature retrieved for this work was obtained from International repositories including NCBI/PubMed, Web of Science, Science Direct and China National Knowledge Infrastructure (CNKI) databases. Results The major active componentes and their potential functions, including hepatoprotective and neuroprotective effects, as well as anti-cancer and anti-inflammatory activities, were summarized and categorized accordingly. As indicated, most of the pharmacological effects were validated in vitro and in vivo. The identification of complex bioactive components in PZH may provide the basis for further therapeutic initiatives. Conclusion Here we have collectively discussed the recent evidences covering most, if not all, pharmacological effects driven by PZH. This review provides novel perspectives on understanding the modes of action and the holistic view of TCM. The rational development of future clinical trials will certainly provide evidence-based medical evidences that will also confirm the therapeutic advantages of PZH, based on the current information available.

show abstract

<p>Combined Therapeutic Effects of <sup>131</sup>I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer</p>

Cited by 14 publications

References 35 publications

Radiotheranostic Agents in Hematological Malignancies

Radiotheranostic Agents in Hematological Malignancies

Controlled-Release Nanosystems with a Dual Function of Targeted Therapy and Radiotherapy in Colorectal Cancer

Pien Tze Huang (PZH) as a Multifunction Medicinal Agent in Traditional Chinese Medicine (TCM): a review on cellular, molecular and physiological mechanisms

Contact Info

Product

Resources

About